Beroni Group (FRA:6B9) EPS (Diluted): €-0.19 (TTM As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6B9 Beroni Group Ltd FRA:6B9
57 GF Score
Price €0.01
View Full Analysis

What is Beroni Group EPS (Diluted)?

Beroni Group FRA:6B9 57 EPS (Diluted) is €-0.19 as of Jun. 2024. GuruFocus rates FRA:6B9 with a GF Score™ of 57/100.

Beroni Group's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was €-0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.19.

Beroni Group's EPS (Basic) for the six months ended in Jun. 2024 was €-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.19.

Beroni Group's EPS without NRI for the six months ended in Jun. 2024 was €-0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.15.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Beroni Group  (FRA:6B9) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Beroni Group EPS (Diluted) Related Terms

Beroni Group EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Beroni Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beroni Group EPS (Diluted) Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial -0.27 -0.32 -0.09 -0.27 -0.29

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.15 -0.11 -0.18 -0.02

FRA:6B9 vs PNXP, CRYM, GCAN: EPS (Diluted) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beroni Group PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beroni Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where Beroni Group's PE Ratio falls into.


FRA:6B9
57GF Score
Beroni Group Ltd FRA:6B9
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beroni Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Beroni Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.663-0)/19.736
=-0.29

Beroni Group's Diluted EPS for the quarter that ended in Jun. 2024 is calculated as

Diluted EPS (Q: Jun. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.337-0)/21.163
=-0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of €-0.19 mean?
Beroni Group (FRA:6B9) has a EPS (Diluted) of €-0.19 as of Jun. 2024. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Beroni Group and its competitors.
Is Beroni Group's EPS (Diluted) too high?
Beroni Group's current EPS (Diluted) is €-0.19. Overall, Beroni Group has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's EPS (Diluted) compare to PNXP and CRYM?
Beroni Group's EPS (Diluted) of €-0.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Beroni Group and its competitors. Beroni Group's current EPS (Diluted) is €-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (FRA:6B9) has a current EPS (Diluted) of €-0.19. The current EPS (Diluted) is €-0.19. Beroni Group's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Beroni Group (FRA:6B9), the current EPS (Diluted) is €-0.19 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beroni Group Business Description

Address 175 Pitt Street, Level 16, Sydney, NSW, AUS, 2000
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
57GF Score

Get the complete analysis for FRA:6B9

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price